I-Mab Shaken by Management Moves, Merger Talk and Delisting Threat

Cancer drug maker has been in a wide range of market-moving headlines lately, though its stock still trades near an all-time low Key Takeaways: I-Mab was placed on a list of stocks at danger of being delisted from the U.S., just a week after it announced two major new executive appointments Company is reportedly exploring a potential sale to a western pharma giant, or a possible merger with a smaller peer By Shirley Lau There’s no shortage of market-moving news these days about up-and-coming cancer drug maker I-Mab (IMAB.US), whose…

Read More »

I-Mab Co-founds a SPAC: What’s Up With That?

Vivere Lifesciences Acquisition Corp, a special purpose acquisition company co-founded by the U.S.-listed drug maker, has filed for a Hong Kong IPO Key Takeaways: Vivere Lifesciences Acquisition Corp., whose co-founders include U.S.-listed I-Mab, could become the first Hong Kong SPAC backed by a U.S.-listed Chinese company The SPAC is targeting Chinese or multinational companies with Chinese operations in the health sector By Fai Pui The Hong Kong Stock Exchange (0388.HK) took a major step this January by allowing special purpose acquisition companies (SPACs) to file for IPOs. Though off-limits to…

Read More »

As U.S. Takes Aim at China Drug Makers, Innovators Appear at Biggest Risk

Washington’s campaign to keep cutting-edge technology out of China took a new twist late last week with the addition of Chinese medical companies to U.S. blacklists Key takeaways: Washington has blacklisted 37 medical-related companies, most of them Chinese, over concerns their skills and technology could be used to help the Chinese military Shares of companies that develop their own drugs are coming under more pressure than peers who license drugs from third-parties following the move   By Doug Young In these troubled times of U.S.-China tensions, sometimes being a copycat has…

Read More »

FAST NEWS: I-Mab to Move Ahead With Dual Listing in Hong Kong

The latest: U.S.-listed cancer drug developer I-Mab (IMAB.US) announced its board has approved a motion to pursue a listing on the Hong Kong Stock Exchange. The board also authorized the company’s senior management to proceed with related preparatory work and undertake other necessary steps for the dual listing. Looking up: The company’s dual listings in the U.S. and Hong Kong would increase its shares’ liquidity by providing near round-the-clock trading. It would also allow the company to raise more capital to support drug research and development. Take Note: The dual-listing means…

Read More »

I-Mab Gets Boost from Latest Industry Signals on New Cancer Treatment

Company’s shares surged as much as 15% after AstraZeneca unveiled upbeat results for a new class of cancer drugs known as CD73 antibodies Key Takeaways: I-Mab’s shares surged up to 15% on positive results from a peer developing a similar new type of cancer treatment, though they later gave back most of those gains Company has plenty of cash on hand, and could soon get more as it seeks a deal to commercialize the drug, uliledlimab, with a U.S. or European partner By Doug Young It may still be at…

Read More »

Drug Maker I-Mab Wins Plaudits as Analysts Urge Caution on Soaring Stock

Cancer specialist’s shares have nearly doubled in the last six months after it posted its first-ever profit and named two well-connected board members Key points: I-Mab’s shares have nearly doubled over the past six months on major licensing deal, fundraising and pending drug approvals Appointment of two new well-connected board members could expedite first approvals of company’s drugs in China By Richard Barbarossa Cancer drug developer I-Mab (IMAB.US) has been on a roll this year. The company’s shares have nearly doubled in the past six months after it recorded its…

Read More »

Pharmaron, I-Mab and Burning Rock Get Investor Validation From MSCI

Three up-and-coming Chinese pharma companies are among those included in latest adjustment for the index compiler’s China All Shares Index Key takeaways: MSCI’s addition of Pharmaron, I-Mab and Burning Rock to its China All Shares Index highlights their strong growth potential Inclusion typically represents validation for a company’s products and outlook By Richard Barbarossa Drug and healthcare R&D firms are well-represented in the latest round of additions to the MSCI China All Shares Index, highlighting the sector’s growth potential and strong fundamentals. Some new ascendants to the list are even…

Read More »